In Vivo
Kainic acid is a potent agonist at excitatory amino acid receptor subtypes in the CNS. HO-I levels are significantly enhanced one, three and seven days after i.c.v, injection of Kainic acid. One day after i.c.v, injection of Kainic acid, the HO-I protein level reaches a maximum and then decreases, but is still significantly enhanced versus the vehicle-injected group. After i.c.v. injection of Kainic acid, HO-I-immunoreactivity is strongly induced not only in the CA3 but also widely in the whole hippocampus.